Oligo Factory has announced the launch of its new low-scale oligonucleotide synthesis capability, expanding its support for researchers developing oligo-based therapeutics and diagnostics. The Massachusetts-based company unveiled this new offering alongside the appointment of new leadership and branded product portfolios at the TIDES USA conference in San Diego.
The new low-scale synthesis platform allows researchers to order custom DNA and RNA oligonucleotides in volumes as small as 50 nanomoles, providing greater flexibility during early-stage research while maintaining the company's standards for quality and service.
"Oligonucleotides are uniquely positioned to address diseases at their genetic root. By targeting specific RNA or DNA sequences, they offer a powerful therapeutic approach for conditions with a known genetic basis—many of which currently have no cure," said Luke Dannenberg, Ph.D., the company's newly appointed CEO.
Strategic Portfolio Expansion
Alongside the new synthesis capability, Oligo Factory introduced three specialized product portfolios:
- FactorTx™: Research-use-only (RUO) and GMP-grade custom oligos manufactured under ICH Q7 guidelines for therapeutic development
- FactorDx™: Custom oligos produced under ISO 13485 standards for molecular diagnostic assay development
- FactorLS™: High-quality RUO-grade oligos (ISO 9001) for life science applications including PCR/qPCR, next-generation sequencing, and agricultural biotechnology
This market-focused approach aims to provide researchers with tailored solutions that match their specific regulatory and quality requirements across different application areas.
Infrastructure and Leadership Investment
The company has significantly expanded its manufacturing infrastructure with a new 13,000-square-foot facility in Holliston, Massachusetts. This investment has increased synthesis capacity 12-fold and enhanced purification and lyophilization capabilities by 10-fold.
To drive commercial growth, Oligo Factory has appointed Luke Dannenberg, Ph.D., as Chief Executive Officer and Baiju Parikh as Vice President of Commercial. Dannenberg brings over 18 years of operational and commercial leadership in diagnostics and life sciences, including previous roles at Dana-Farber Cancer Institute, Foundation Medicine, and Roche Diagnostics.
Parikh joins with more than two decades of experience in molecular diagnostics, genomics, and precision medicine, having previously founded InterpretBio and held senior positions at IBM Watson for Genomics, GenomOncology, and Roche Diagnostics.
Addressing Market Needs
The expansion into low-scale synthesis addresses a critical need in the oligonucleotide market, particularly for companies in early-stage research and development that require high-quality, customizable oligos in smaller quantities.
"With the launch of our new low-scale synthesis capability and rapid turnaround times, we're enabling therapeutic developers to accelerate innovation and bring life-changing treatments to patients faster," Dannenberg noted.
Baiju Parikh, VP of Commercial, emphasized the broader applications: "Our small-scale synthesis capability is built on the same foundation of expertise and quality that supports therapeutic developers. This expansion also allows us to better meet the growing needs of the molecular diagnostics market, including qPCR and next-generation sequencing applications."
Market Positioning
By offering flexible production scales with consistent quality standards, Oligo Factory positions itself as an alternative to larger suppliers that may struggle to meet specialized needs or provide the personalized service required by innovative therapeutic and diagnostic developers.
The company's approach allows customers to start with small-scale orders during discovery and then scale up through preclinical testing, toxicology studies, and eventually clinical development, maintaining consistency throughout the development lifecycle.
Founded in 2006, Oligo Factory has built its reputation on delivering high-quality custom oligonucleotides with technical expertise and responsive service. The recent expansions in capabilities, infrastructure, and leadership signal the company's strategic focus on supporting the growing oligonucleotide therapeutics and diagnostics markets.
